Blue Wave Therapeutics develops targeted cancer therapies using a novel biopolymer-radionuclide platform. Their approach aims to deliver radiation directly to tumors, potentially improving survival rates for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack precision, damaging healthy tissues alongside tumors, leading to significant side effects and reduced quality of life for patients. This is particularly challenging in treating solid tumors like glioblastoma, where complete surgical removal is difficult and residual cancer cells often lead to recurrence.
Solution
Blue Wave Therapeutics is developing targeted radionuclide therapies for solid tumors, utilizing a proprietary radioactive biopolymer platform to deliver radiation directly to cancer cells. Their technology employs targeted alginate nanoparticles, designed to bind to cancer cell receptors, enabling precise delivery of alpha or beta radiation while minimizing harm to healthy tissues. The lead candidate, ARAspheres, consists of integrin-targeting alginate nanospheres loaded with Actinium-225, designed to deliver targeted alpha radiation to glioblastoma cells after surgery. This approach aims to improve patient outcomes by selectively irradiating residual tumor cells in the surgical cavity, preventing recurrence and improving survival rates. Blue Wave Therapeutics is also exploring applications of their platform for other solid tumors, including liver, prostate, thyroid, pancreatic, and breast cancers.
Target Audience
The primary target audience includes oncologists, nuclear medicine specialists, and hospitals focused on providing advanced cancer treatments, particularly for patients with solid tumors such as glioblastoma.
Features
- Targeted delivery of radionuclides using biopolymer nanoparticles
- Alginate nanoparticles designed to bind specifically to cancer cell receptors
- Utilizes radionuclides such as Actinium-225 to induce irreversible DNA damage in cancer cells
- ARAspheres: Integrin-targeting alginate nanospheres loaded with Actinium-225 for glioblastoma treatment
- Platform adaptable to different cancer indications through incorporation of various radionuclides and targeting peptides
- Demonstrated efficacy across multiple cancer types in preclinical studies
- Key R&D milestones include validation of ARAspheres labeling and stability testing of radiolabeled ARAspheres
- Production of RGD-alginate nanospheres (<200nm) for animal model testing